Merck Clinical Trials Logo Merck Clinical Trials

Clinical Trial Finder

Merck Clinical Trial Finder
  • About clinical trials
    • About Clinical Trials
    • How does participation work?
    • What to consider
    • Frequently asked questions
  • Resources
    • Resources
    • For patients
    • For caregivers
  • Our medical science
  • For HCPs
  • English
    • Back
    • English
    • Español

Condition: Gastroesophageal Junction Carcinoma

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to Overall Survival (OS) and Event-free Survival (EFS) in:

  • participants with esophageal squamous cell carcinoma (ESCC),
  • participants whose tumors express Programmed Death-Ligand 1 (PD-L1) Combined Positive Score (CPS) ≥10, and
  • all participants.

The primary study hypotheses are that dCRT+ pembrolizumab is better than dCRT + placebo with respect to:

  • OS in participants with ESCC,
  • OS in participants whose tumors express PD-L1 CPS ≥10,
  • OS in all participants,
  • EFS in participants with ESCC,
  • EFS in participants whose tumors express PD-L1 CPS ≥10, and
  • EFS in all participants.

Study of Pembrolizumab Versus Placebo in Participants With Esophageal Carcinoma Who Are Receiving Chemotherapy and Radiation Therapy

October 9, 2022

By clique_admin

The purpose of this study is to assess the efficacy and safety of treatment with definitive chemoradiotherapy (dCRT) + pembrolizumab (MK-3475) compared to treatment with dCRT + placebo with respect to

Merck Clinical Trials Logo Merck Clinical Trials
  • Merck.com
  • Privacy Policy
  • Terms of Use
  • Policies & Perspectives
  • Cookie Preferences
  • Accessibility

Copyright © 2023 Merck & Co., Inc., Rahway, NJ, USA and its affiliates. All rights reserved.

THIS WEBSITE IS INTENDED FOR A UNITED STATES AUDIENCE ONLY

Merck Essential Accessibility

Merck Essential Accessibility